Physician

Lorraine C Snyder Dougherty, MD

According to 2025 Medicare claims, Lorraine Dougherty, MD (NPI: 1013954643) practices hematology/oncology in the Montgomery County-Bucks County-Chester County, PA market, with the plurality of this provider's patient population coming from Bucks, PA. This provider's primary affiliated billing organization is ALLIANCE CANCER SPECIALISTS P.C. (NPI: 1487923686; TIN: 452552343) and primary practice location at 18901-2554.

Dougherty's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 713 traditional Medicare patients, billed 186,494 HCPCS/CPT codes, and received $3,144,700 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,352 prescription claims across 331 beneficiaries totaling $3,124,794 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 27 claims. Open Payments data shows 40 records totaling $994. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,021,404 to $3,124,794. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	711	170,404	$2,303,439
2016	745	155,040	$2,686,885
2017	754	177,188	$2,396,714
2018	739	261,567	$3,601,287
2019	777	224,543	$3,180,100
2020	707	186,803	$2,764,465
2021	669	216,373	$3,281,624
2022	599	202,354	$2,593,412
2023	711	216,972	$2,952,843
2024	713	186,494	$3,144,700

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	227	1,145	$1,021,404
2016	250	1,260	$1,461,772
2017	208	1,066	$1,706,577
2018	236	1,147	$1,612,968
2019	266	1,165	$1,716,183
2020	261	1,266	$2,483,699
2021	260	1,274	$2,913,849
2022	266	1,371	$3,529,069
2023	266	1,225	$2,581,498
2024	331	1,352	$3,124,794

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	34	$1,094
2017	N/R	14	$9,971
2018	N/R	11	$69
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	34	$2,558
2022	N/R	47	$1,454
2023	N/R	39	$11,110
2024	N/R	27	$839

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	217	481	$105
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	310	405	$69
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	84	168	$53
96375	Injection of additional new drug or substance into vein	96	686	$13
96372	Injection of drug or substance under skin or into muscle	101	455	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	26	728	$396,224
Jakafi	Ruxolitinib Phosphate	21	630	$355,002
Ibrance	Palbociclib	18	483	$281,594
Lenalidomide	Lenalidomide	14	385	$248,343
Pomalyst	Pomalidomide	14	392	$208,066

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$501
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	16	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	40	$994	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Lorraine C. Snyder Dougherty, MD?

Tedicare shows public-source Medicare data for Lorraine C. Snyder Dougherty, MD (NPI 1013954643), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lorraine C. Snyder Dougherty, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Lorraine C. Snyder Dougherty, MD?

Lorraine C. Snyder Dougherty, MD is linked to ALLIANCE CANCER SPECIALISTS P.C. (billing NPI 1487923686) in the available physician profile data.

Does Lorraine C. Snyder Dougherty, MD have Open Payments data?

Lorraine C. Snyder Dougherty, MD has 40 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.